Kidney injuries on Ozempic
Recent reports of kidney injuries have caused a change in requirements for GLP1 labeling. We dive into the actual risk and what you can do about it.
The FDA updated the required drug safety related labels for Ozempic back in January, and the news seems to have been circulating as recently as two weeks ago on the widespread labeling changes.
We deep dive into what the new labeling means and just how prevalent the case of kidney injuries are for those on Ozempic, and look back to our article on kidney benefits (including kidney cancer).
The FDA updated it’s required labeling, due to increases in reported side effects for people on Ozempic.
Some news sites picked up this changed labeling as recently as 2 weeks ago:
📰 New kidney injury warnings added to all GLP-1 drugs by FDA
📰 FDA SIDE EFFECTS UPDATE: Kidney Risks Tied to Dehydration From GLP-1 Drugs
While the news articles are new, the actual change is very old:
🏛️ Drug Safety-related Labeling Changes (SrLC) for Ozempic
Want to get into the research on what the actual risk of kidney damage is and GLP1's effect of kidney cancer? The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:
